Active Ingredient: Norfloxacin
Cited By This article is cited by 401 publications. Organic Letters . DOI: 10.
Organic Letters . Rashmi A. Agarwal, Anoop K. Gupta, Dinesh De. Inorganic Chemistry .
Organic Letters . Santosh J. Gharpure, Santosh K. Nanda, Priyanka A.
Adate, and Yogesh G. The Journal of Organic Chemistry .
Sean W. Reilly and Robert H.
Pregnancy Norfloxacin has been reported to rapidly cross the blood-placenta and blood-milk barrier, and is extensively distributed into the fetal tissues. For this reason norfloxacin and other fluoroquinolones are contraindicated during pregnancy due to the risk of spontaneous abortions and birth defects.
The manufacturer only recommends use of norfloxacin during pregnancy when benefit outweighs risk. Ciprofloxacin is being licensed for the treatment of Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli and Inhalational Anthrax post-exposure and levofloxacin was recently licensed for the treatment of Inhalational Anthrax post-exposure.
However, the Fluoroquinolones are licensed to treat lower respiratory infections in children with cystic fibrosis in the UK.
Adverse effects In general, fluoroquinolones are well tolerated, with most side-effects being mild to moderate.
The overall rate of adverse events in patients treated with fluoroquinolones is roughly similar to that seen in patients treated with other antibiotic classes.Users are not otherwise permitted to redistribute this material, requesters must process Supporting Information from the ACS website, either in whole or in part, in either machine-readable form or any other form without permission from the American Chemical Society.
Centers for Disease Control study found patients treated with fluoroquinolones experienced adverse events severe enough to lead to an emergency department visit more frequently than those treated with cephalosporins or macrolides, but less frequently than those treated with penicillins, clindamycin, sulfonamides, or vancomycin.
Uygun, et al. Solomon.